JP2014506448A - 凝固因子の阻害剤に対する結合タンパク質 - Google Patents

凝固因子の阻害剤に対する結合タンパク質 Download PDF

Info

Publication number
JP2014506448A
JP2014506448A JP2013549784A JP2013549784A JP2014506448A JP 2014506448 A JP2014506448 A JP 2014506448A JP 2013549784 A JP2013549784 A JP 2013549784A JP 2013549784 A JP2013549784 A JP 2013549784A JP 2014506448 A JP2014506448 A JP 2014506448A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013549784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506448A5 (enExample
Inventor
フランク・ディットマー
アンヤ・ビュッフミュラー
クリストフ・ゲルデス
アドリアン・テルステーゲン
マルク・イェアン・グノート
ラルス・リンデン
アクセル・ハレンガ
ヨアンナ・グルジンスカ−ゲーベル
マリオ・イェスケ
マルティナ・シェフェル
イェルク・ビルケンフェルト
ホルガー・パウルゼン
リカルダ・フィナーン
アンケ・マイヤー−バルトシュミット
アンドレア・アイカー
ジモーネ・グレフェン
ズザンネ・シュタイニヒ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of JP2014506448A publication Critical patent/JP2014506448A/ja
Publication of JP2014506448A5 publication Critical patent/JP2014506448A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013549784A 2011-01-19 2012-01-17 凝固因子の阻害剤に対する結合タンパク質 Pending JP2014506448A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11151410.5 2011-01-19
EP11151410 2011-01-19
PCT/EP2012/050595 WO2012098089A1 (en) 2011-01-19 2012-01-17 Binding proteins to inhibitors of coagulation factors

Publications (2)

Publication Number Publication Date
JP2014506448A true JP2014506448A (ja) 2014-03-17
JP2014506448A5 JP2014506448A5 (enExample) 2015-03-05

Family

ID=45491612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013549784A Pending JP2014506448A (ja) 2011-01-19 2012-01-17 凝固因子の阻害剤に対する結合タンパク質

Country Status (7)

Country Link
US (1) US20140050743A1 (enExample)
EP (1) EP2665751A1 (enExample)
JP (1) JP2014506448A (enExample)
CN (1) CN103619883A (enExample)
AR (1) AR084886A1 (enExample)
CA (1) CA2824885A1 (enExample)
WO (1) WO2012098089A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102039189B1 (ko) * 2016-03-23 2019-11-01 서울대학교산학협력단 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
AU2018216008A1 (en) 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
NL2036011B1 (en) * 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539945A (ja) * 2007-09-28 2010-12-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤に対する抗体およびその使用の方法
JP2013517317A (ja) * 2010-01-20 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗凝固薬の解毒剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6669937B2 (en) * 2000-04-20 2003-12-30 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
KR100863113B1 (ko) 2001-06-20 2008-10-13 다이이찌 산쿄 가부시키가이샤 디아민 유도체
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
CA2743496C (en) * 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539945A (ja) * 2007-09-28 2010-12-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤に対する抗体およびその使用の方法
JP2013517317A (ja) * 2010-01-20 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗凝固薬の解毒剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015048481; ＥＩＧＥＮＢＲＯＴ　Ｃ．，　ｅｔ　ａｌ．: Ｊ　Ｍｏｌ　Ｂｉｏｌ Ｖｏｌ．３３１, 2003, ｐ．４３３-４４６ *

Also Published As

Publication number Publication date
WO2012098089A1 (en) 2012-07-26
CA2824885A1 (en) 2012-07-26
CN103619883A (zh) 2014-03-05
AR084886A1 (es) 2013-07-10
EP2665751A1 (en) 2013-11-27
US20140050743A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
TWI820482B (zh) 凝血因子xi抗體及使用方法
US8241628B2 (en) Compositions and methods for antibodies targeting complement protein C5
US20100291106A1 (en) Compositions and methods for antibodies targeting complement protein c3b
JP7139332B2 (ja) 第ｘｉ因子抗体および使用方法
EP2525812A2 (en) Anticoagulant antidotes
TW201802121A (zh) 抗因子XI/XIa抗體之逆轉結合劑及其用途
AU2014281294A1 (en) Lectin-like oxidized LDL receptor1 antibodies and methods of use
WO2022130182A1 (en) Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
US20140050743A1 (en) Binding proteins to inhibitors of coagulation factors
US20210395390A1 (en) Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
US12215168B2 (en) Anti-A2AP antibodies and uses thereof
HK1190726A (en) Binding proteins to inhibitors of coagulation factors
US12065505B2 (en) Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof
RU2844816C1 (ru) Новые антитела против a2ap и их применение
TW201245226A (en) Binding proteins to inhibitors of coagulation factors
BR112023002800B1 (pt) Anticorpos anti-a2ap e seu método de produção, conjugado deanticorpo, sequências de ácido nucleico isoladas, vetor, composiçãofarmacêutica, seu uso, e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150116

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150226

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160815